Frailty is defined as a geriatric condition or syndrome characterised by a decline in functional reserve and adaptive capacity in older people. This decline leads to a general worsening in health that tends to progress towards dependency. Unlike dependency, frailty is reversible and there is substantial evidence of the effectiveness of interventions based on muscle strengthening through exercise, improving diet, and reducing polypharmacy, among other approaches. Frailty is independently associated with an elevated risk of death, loss of independence, falls and fractures, hospitalisations and reductions in health-related quality of life.
It is very important to identify frail older individuals as it makes it possible, through personalised interventions tailored to the needs of individuals and their families, to slow the natural progression of frailty towards dependency.
This invention provides a new method for the diagnosis of frail individuals and distinguishing them from more robust or dependent individuals based on measurements of the level of protein expression and/or transcription of a range of molecular markers identified by complete transcriptome analysis.
The organization is offering a license agreement to experienced companies from the health sector interested in acquiring this technology. Although it is not compulsory, it would be preferable for the partner to be a healthcare facility so that the validation of the method can be carried out.